BUSINESS
Short Call: Bulls chant 'all is well', RBI's rates dilemma, yen carry trade; Cummins, BSE, PB Fintech in focus
There is a time to go long, a time to go short and a time to go fishing. - Jesse Livermore
BUSINESS
Dr Lal Pathlabs drops 4% as valuation concerns outweigh Q1FY25 positives
Several brokerages downgraded shares of Dr Lal PathLabs due to its high valuations, which they believe limit the potential for further upside. However, recognising growth prospects, price targets were raised.
BUSINESS
Analysts Call Tracker: Street remains pessimistic on Dr Reddy’s, Divi’s Labs despite positive Q1 results
Dr Reddy's Laboratories and Divi's Laboratories remained on the list of 10 Nifty 50 stocks that analysts on the Street view with most pessimism.
BUSINESS
Lupin stock soars to 52-week high on strong all-round Q1 show
Alongside strong topline and bottomline growth, Lupin's operational performance also improved significantly in Q1. Its EBITDA margin came at a multi-quarter high of 23.3 percent.
BUSINESS
How major economies reacted to the global market selloff
The global market sell-off was especially severe in Japan, South Korea, and Taiwan, with each of these equity markets witnessing record single-day declines.
BUSINESS
The only pocket of green – is the shift towards defensive for real?
Pharma and consumer goods sectors are witnessing optimism, driven by recovering rural demand and strong domestic growth. On top of that, reasonable valuations and earnings visibility for these sectors are bringing the defensive play back in focus.
BUSINESS
Divi's Labs plans to foray into peptide fragments, expects API pricing to stabilise
API prices have remained under pressure for the past two years on the back of inventory destocking from Chinese companies post-COVID.
BUSINESS
US Biosecure Act spurs growth opportunities for Divi's Labs
The US Biosecure Act aims to prohibit US life sciences companies from signing contracts with certain Chinese biotech companies to safeguard against the potential misuse of US genomic data by the Chinese government and military.
BUSINESS
Divi's Labs Q1 Preview: Low base, strong custom synthesis sales to aid profit growth
Growth expectations for the CDMO player span a vast range as the most optimistic brokerages are predicting as much as 61 percent on year growth while the most pessimistic are baking in forecasts of just 10 percent increase.
BUSINESS
Brokerages go neutral over Sun Pharma as uncertainty looms over Leqselvi launch
Leqselvi secured approval from the US regulator last week, but its launch timeline has been muddled by a preliminary injunction filed by US pharmaceutical company Incyte, which alleges patent infringement.
BUSINESS
Short Call: All news is good news for market; auto in low gear, ACC, Ambuja Cements, Ashok Leyland in focus
“Most investors are primarily oriented toward return, how much they can make, and pay little attention to risk, how much they can lose." - Seth Klarman
BUSINESS
Sun Pharma's R&D spending to go up in coming quarters
Sun Pharma had previously guided to increase its R&D spend to 10 percent of total revenues for FY25 as compared to 7-8 percent in FY24.
BUSINESS
Sun Pharma Q1 Preview: Strong US, domestic sales to aid profit growth but high R&D to drag margins
Sun Pharma's performance in the US market will be driven by ramp-up of Revlimid, resumption of supplies from Mohali unit and growth in its specialty portfolio. Back home, its robust foothold in the chronic segment promises to fuel double-digit growth.
BUSINESS
MC Markets Graphixstory: A history of capital gains tax and why markets fear more hikes
Back in 2018, then finance minister Arun Jaitley reintroduced capital gains tax on equities, and now, in 2024, Nirmala Sitharaman has gone a step ahead and hiked tax rates.
BUSINESS
Brokerages give thumbs up to Colgate on strong Q1 volume growth; stock hits record high
Colgate's growth in rural markets has outpaced urban markets for the second consecutive quarter. Its toothpaste portfolio saw double-digit growth driven by high single-digit volume growth, higher than industry rival Hindustan Unilever's mid-single digit growth which was driven by pricing.
BUSINESS
Dr Reddy's Labs targets double-digit India growth for FY25
With sales of Rs 1,330 crore in Q1 of FY25, Dr. Reddy's ranks 10th in the domestic market, according to IQVIA data.
BUSINESS
Cipla forecasts US sales run-rate at $235-$240 mn, margin to be stable at current levels
Cipla is aiming for a Q4 FY25 launch for its important respiratory drug, Advair, while awaiting the US FDA's response on corrective measures at its Goa facility, crucial for launching the chemotherapy drug Abraxane.
BUSINESS
Dr Reddy's Labs Q1 Preview: Tepid US sales likely to put brakes on earnings growth
Analysts will focus on Dr Reddy's R&D expense and margin guidance for FY25.
BUSINESS
Short Call: FOMO, not fundamentals, driving retail frenzy, Nasdaq crash a warning; HUL, KNR Constructions, Coforge, Kajaria in focus
“At the root of all financial bubbles is a good idea carried to excess.” - Seth Klarman
BUSINESS
Cipla Q1 Preview: Domestic business restructuring may moderate profit growth
Cipla's US sales are expected to remain on a strong footing in Q1, but a restructuring of the domestic trade generics business is expected to negatively impact revenue, potentially slowing the drugmaker's growth momentum.
BUSINESS
Torrent Pharma's well rounded Q1 performance wins over brokerages
Torrent Pharma's robust Q1 FY25 performance, strong domestic growth, robust margin profile and expansion into the US market are factors driving bullishness for the drugmaker.
BUSINESS
Don't think hike in capital gains tax big enough to deter market investments, says Rahul Arora
Budget 2024: "I think prima facie hiking the rates is negative, but I think the way the market has reacted from the day's is low is telling you that people are ready to buy into equities," says Rahul Arora.
BUSINESS
Eris Lifesciences: Why mutual funds are hiking stake continuously?
Mutual funds are ramping up their stakes in Eris Lifesciences due to its strategic acquisitions and growth prospects in dermatology and cardiometabolic segments, boosting optimism for sustained profitability and market expansion.
BUSINESS
LTIMindtree rises 3.5% as Street cheers steady Q1 results, positive commentary
While LTIMindtree's management commentary stands to be the most encouraging among IT majors that have released their Q1 earnings so far, concerns over the company's margins continue to irk analysts.
